$3.67 Earnings Per Share Expected for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) This Quarter

Brokerages forecast that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will report earnings of $3.67 per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Jazz Pharmaceuticals’ earnings. The highest EPS estimate is $4.29 and the lowest is $3.35. Jazz Pharmaceuticals posted earnings per share of $4.00 in the same quarter last year, which suggests a negative year over year growth rate of 8.3%. The business is expected to announce its next earnings results on Tuesday, February 22nd.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year earnings of $15.50 per share for the current financial year, with EPS estimates ranging from $14.22 to $15.81. For the next year, analysts anticipate that the firm will post earnings of $17.14 per share, with EPS estimates ranging from $15.27 to $18.16. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 9th. The specialty pharmaceutical company reported $4.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $1.60. Jazz Pharmaceuticals had a negative net margin of 5.62% and a positive return on equity of 21.43%. The business had revenue of $838.12 million during the quarter, compared to the consensus estimate of $829.98 million. During the same quarter in the prior year, the firm posted $3.86 earnings per share.

A number of research firms have recently commented on JAZZ. The Goldman Sachs Group began coverage on Jazz Pharmaceuticals in a research report on Thursday, November 18th. They issued a “buy” rating for the company. Citigroup initiated coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, October 5th. They issued a “buy” rating and a $200.00 price target for the company. HC Wainwright decreased their price objective on shares of Jazz Pharmaceuticals from $220.00 to $210.00 and set a “buy” rating on the stock in a report on Monday, August 16th. Needham & Company LLC initiated coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, September 22nd. They set a “buy” rating and a $220.00 target price for the company. Finally, TheStreet downgraded shares of Jazz Pharmaceuticals from a “b” rating to a “c” rating in a research report on Monday, August 9th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $210.36.

NASDAQ JAZZ traded down $0.24 during trading hours on Thursday, reaching $129.31. The company’s stock had a trading volume of 288,927 shares, compared to its average volume of 681,663. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -50.71, a P/E/G ratio of 0.69 and a beta of 0.91. The company’s 50-day moving average is $134.84 and its two-hundred day moving average is $154.25. The company has a debt-to-equity ratio of 1.59, a current ratio of 3.58 and a quick ratio of 2.03. Jazz Pharmaceuticals has a 1-year low of $126.01 and a 1-year high of $189.00.

In other news, CEO Bruce C. Cozadd sold 6,598 shares of the stock in a transaction on Monday, October 4th. The stock was sold at an average price of $129.87, for a total transaction of $856,882.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kim Sablich sold 2,748 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, November 11th. The shares were sold at an average price of $135.01, for a total transaction of $371,007.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,162 shares of company stock valued at $2,146,536. Insiders own 4.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in JAZZ. Polaris Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at $229,646,000. JPMorgan Chase & Co. grew its position in Jazz Pharmaceuticals by 50.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,884,972 shares of the specialty pharmaceutical company’s stock valued at $512,487,000 after acquiring an additional 967,343 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Jazz Pharmaceuticals during the third quarter worth about $97,566,000. Victory Capital Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 714.9% during the second quarter. Victory Capital Management Inc. now owns 731,707 shares of the specialty pharmaceutical company’s stock worth $129,981,000 after purchasing an additional 641,921 shares in the last quarter. Finally, Farallon Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $74,859,000. Institutional investors own 91.42% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.

Featured Story: What Does Beta Mean In Stock Selection?

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.